Novartis buys Amblyotech to develop digital therapy for amblyopia
By Akshay Kedari  Date: 2020-04-21

Novartis buys Amblyotech to develop digital therapy for amblyopia

Novartis has recently made an announcement confirming that it has concluded its acquisition of Amblyotech, which is a software startup based in the U.S. Novartis will collaborate with McGill University and Ubisoft to be able to continue with the development of Amblyotech’s acquired digital tech for treating amblyopia, or “lazy eye”.

Apparently, there have been estimations regarding the amblyopia affecting about 3% of the world population. Some of these people can be appropriate candidates for the therapy when it gets approved. The condition generally results in poor vision and various other problems with the quality of life, if it is left untreated.

The condition is capable of impacting both adults and children beyond their vision that makes it difficult to both maintain and drive a sense of autonomy. There are various options for treatment currently, that include atropine and patching, which are mostly associated with a lower sense of compliance as well as a low rate of success. The adults have a limited set of approved therapies.

Reportedly, Amblyotech is aimed at improving compliance and it uses passive video and active gaming technology with 3D glasses, which trains the eyes for working together in order to view a complete image. The software employs a visual representation, which is called dichoptic display, wherein each eye is offered different images by using a proprietary algorithm.

The software of Amblyotech had shown big improvements in children as well as adults vision in the early clinical study as compared to the ones with standard care and treatment.

Global Business Franchise Head for Ophthalmology, Nikos Tripodis stated that the software of Amblyotech is an excellent example how the company can recreate medicines by using digital technology, as the firm offers a solution that is non-invasive and has the potential to be considerably faster than compared to the current care standards like patching for adults and children who have been impacted by lazy eye.

 

Source Credit- https://www.globenewswire.com/news-release/2020/04/20/2018335/0/en/Novartis-acquires-Amblyotech-pursuing-novel-digital-therapy-for-children-and-adult-patients-with-lazy-eye.html

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Rivian secures USD 2.65 billion months before its first vehicle launch
Rivian secures USD 2.65 billion months before its first vehicle launch
By Akshay Kedari

Electric vehicle startup, Rivian, backed by Ford Motor Co. and Amazon.com Inc., has reportedly announced an investment round of USD 2.65 billion led by T. Rowe Price, months before its first vehicle launch. Sources with knowledge of the matter state...

BMW drivers can now unlock and start cars without using their iPhone
BMW drivers can now unlock and start cars without using their iPhone
By Akshay Kedari

German multinational automobile manufacturer, Bayerische Motoren Werke AG, commonly known as BMW, has reportedly unveiled an upgraded version of its mobile car key technology, called the Digital Key Plus. This product enables iPhone users to unlock t...

FMCG firms resort to marginal hike to cope with raw material inflation
FMCG firms resort to marginal hike to cope with raw material inflation
By Akshay Kedari

The recent inflation in raw materials has reportedly prompted players in the FMCG sector to take price hike measures for their products, in a bid to maintain the revenues. According to reliable sources, some FMCG companies, including Marico, have al...

boAt raises USD 100 million in funding from Warburg Pincus
boAt raises USD 100 million in funding from Warburg Pincus
By Akshay Kedari

Indian consumer electronics brand, boAt, has reportedly secured funding of USD 100 million from Warburg Pincus, a New-York-based private equity firm, at a USD 300 million valuation. The company will utilize these funds to expand its product portfoli...

Elevar Therapeutics and Inceptua partner to commercialize Apealea®
Elevar Therapeutics and Inceptua partner to commercialize Apealea®
By Akshay Kedari

According to reliable sources, U.S.-based fully integrated biopharmaceutical company, Elevar Therapeutics Inc., has signed an exclusive agreement with Inceptua Group for the commercialization and distribution of its non-cremophor based paclitaxel tre...